Kodiak Sciences (NASDAQ: KOD)
Kodiak Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kodiak Sciences Company Info
Kodiak's portfolio of candidate eye treatments centers on its innovative antibody biopolymer conjugate platform.
News & Analysis
Why Kodiak Sciences Stock Is Sharply Lower Today
An analyst downgrade is weighing on the drugmaker's stock price today.
Why Kodiak Sciences Stock Is Cratering Today
A disappointing clinical trial result is weighing heavily on the drugmaker's shares today.
Is This Mid-Cap Biotech Stock a Buy Now?
This mid-cap growth stock could be a long-term winner.
Why Kodiak Sciences Stock Is Tumbling Today
The company provided a first-quarter update with news that it's launching another late-stage clinical study of its lead candidate.
2 Top Healthcare Stocks That Jumped Last Week
Despite recent run-ups, these two have what takes to keep rising.
Billionaires Are Gobbling Up These 3 Healthcare Stocks
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
These Were the 10 Best Stocks of 2019
Seven biotechs led the way.
3 Best Biotech Stocks of 2019: Are They Buys Now?
These stocks have soared 935% or more this year. Can they keep the momentum going?
Valuation
Earnings Transcripts
Kodiak Sciences Inc. (KOD) Q1 2020 Earnings Call Transcript
KOD earnings call for the period ending March 31, 2020.
Kodiak Sciences Inc. (KOD) Q3 2019 Earnings Call Transcript
KOD earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.